China mulls 'substantive' new requirements for multi-regional drug trials
This article was originally published in SRA
Executive Summary
Chinese regulators are proposing to introduce a host of new requirements for international drug companies that conduct multi-regional clinical trials (MRCTs) involving study sites in China1,2.